Source: DGNews  |  Posted 8 years ago

HELSINKI, FINLAND -- September 4, 2003 -- Rasagiline added to levodopa therapy reduced the total time when Parkinson's symptoms are not adequately controlled ("off" time) by 1.2 hours daily or 21 percent, a significant portion of the day, according to an abstract presented at the 7th Conference of the European Federation of Neurological Societies (EFNS) in Helsinki.

"The data presented on rasagiline is good news for patients and neurologists. This treatment may offer the advantage of a well tolerated, once-daily therapy that reduces 'off' time and increases motor function," said Dr. Warren Olanow, professor and chairman of the Department of Neurology at Mount Sinai School of Medicine.

The 18-week LARGO trial conducted in Europe, Israel, and Argentina included 687 patients and compared the effects of once-daily rasagiline to placebo and Comtan